STOCK TITAN

Mainz Biomed N.V. - MYNZ STOCK NEWS

Welcome to our dedicated news page for Mainz Biomed N.V. (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mainz Biomed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mainz Biomed N.V.'s position in the market.

Rhea-AI Summary
Mainz Biomed announces positive interim results from its CRC screening campaign in partnership with Zöller-Kipper GmbH. Almost half of Zöller-Kipper's employees in Germany have participated in the screening program using ColoAlert®, Mainz Biomed's at-home CRC screening test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed appoints Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA to focus on the commercialization of ColoAlert®, a at-home detection test for colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
management
-
Rhea-AI Summary
Mainz Biomed presents groundbreaking results of its ColoFuture Study, showing enhanced effectiveness in non-invasive colorectal cancer screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
Rhea-AI Summary
Mainz Biomed announces participation in UEG Week
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. to attend JonesTrading 2023 Healthcare Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
conferences
-
Rhea-AI Summary
Mainz Biomed announces the live launch of ColoAlert®, an at-home detection test for colorectal cancer, in collaboration with Bioclinica in Romania. The potential market for ColoAlert® in Romania is substantial, reaching 9.2 million tests per year. The collaboration with Bioclinica adds significant value to Mainz Biomed's mission. Colorectal cancer is a significant public health concern in Europe. ColoAlert® provides an efficient and user-friendly screening test against CRC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
Rhea-AI Summary
Mainz Biomed to present positive results from ColoFuture study at the 4th International Conference on Gastroenterology. Clinical trial showed sensitivity of 94% and specificity of 97% for colorectal cancer, and 81% sensitivity for advanced adenomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
-
Rhea-AI Summary
Mainz Biomed N.V. CEO to present at Cantor Fitzgerald Global Healthcare Conference on September 28th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
conferences
-
Rhea-AI Summary
Mainz Biomed announces positive results from its ColoFuture study, with sensitivity for colorectal cancer of 94% and sensitivity for advanced adenoma of 81%. The company eagerly awaits results from its eAArly DETECT clinical trial. The portfolio of mRNA biomarkers acquired from Université de Sherbrooke enhances ColoAlert®'s technical profile to increase diagnostic rates for CRC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
clinical trial
Rhea-AI Summary
Mainz Biomed announces strategic partnership with Ärztliches Labor Dr. Buhlmann to strengthen its position in the German market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
partnership
Mainz Biomed N.V.

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

20.97M
14.78M
17.83%
1.14%
1.56%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mainz

About MYNZ

mainz biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. we develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.